Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Dev Dyn. 2011 Sep 8;240(10):2324–2334. doi: 10.1002/dvdy.22734

Figure 2.

Figure 2

Gal4 drives strong expression in stable transgenic lines and can be inhibited by Gal80. Confocal maximum projections of 72hpf embryos; ventral views, anterior to the top. Embryos are heterozygous for the genotypes shown. Scale bar, 50μm. Arrow points to ectopic GFP expression in eyes driven by Gal4-VP16 (A, D) not noted using native Gal4 (E). (A-C) Live embryos imaged with identical laser power settings, showing that Gal4-driven expression (B) is stronger than a direct enhancer:GFP construct (C) and is comparable to Gal4-VP16-driven expression (A). (D-F) Immunohistochemistry for GFP in fixed embryos again shows that Gal4-dependent expression (E) is comparable to Gal4-VP16 (D), but has minimal expression in other tissues (such as eye muscles, arrow). (F) The original transgenic enhancer line Tg(otpb.A:egfp)zc48 shows dimmer expression compared to Gal4-driven expression in (E). (G) A weakly-expressing allele of elavl3:Gal80 only partially inhibits Gal4-dependent transgene expression. (H) A strongly-expressing elavl3:Gal80 allele completely inhibits Gal4-dependent expression. Insets for (G) and (H) show relative levels of Gal80 in situ expression. (I) Gal80 is unable to inhibit Gal4-VP16-driven expression.